Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Tianjin TEDA Biomedical Engineering Co's annulizedROA % for the quarter that ended in Dec. 2025 is
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Tianjin TEDA Biomedical Engineering Co Asset Turnover Related Terms
Tianjin TEDA Biomedical Engineering Co Asset Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co Asset Turnover Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
HKSE:08189 vs CTVA, CF, MOS: Asset Turnover Comparison
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co Asset Turnover vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a Asset Turnover of 0.88 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors.
Is Tianjin TEDA Biomedical Engineering Co's Asset Turnover too high?
Tianjin TEDA Biomedical Engineering Co's current Asset Turnover is 0.88. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's Asset Turnover compare to CTVA and CF?
Tianjin TEDA Biomedical Engineering Co's Asset Turnover of 0.88 can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for an Agriculture company?
A good Asset Turnover depends on the Agriculture industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. Tianjin TEDA Biomedical Engineering Co's current Asset Turnover is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current Asset Turnover is 0.88. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current Asset Turnover is 0.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for HKSE:08189:
Asset Turnover: 0.88
GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for HKSE:08189
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08189 has been successfully added to your 
